List view / Grid view
Scientists reveal that some patients who develop severe COVID-19 symptoms mount ineffective immune responses due to a lack of type I interferons, either through genetic mutation or inactivation by auto-reactive antibodies.
After finding that the circular RNA called CDR1as plays a role in driving metastasis, researchers have identified it as a potential target for lung squamous cancer.
A natural pigment from Monascus purpureus can be used to stain cells and distinguish between live and dead ones in toxicology studies.
A new interactive map of the surface of SARS-CoV-2, featuring the Spike, Envelope and Membrane proteins, has been released for researchers to use.
Researchers have discovered that disrupting the Gdpd3 gene significantly reduced chronic myelogenous leukaemia relapse in mice.
Researchers have identified two molecules that explain why children experience COVID-19 differently to adults.
Scientists have found a hormone peptide called YY that presents a promising drug target for malabsorption in babies.
Researchers report that reduced TDP-43 expression disrupts axonal transport of messenger RNAs to cause neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).
Scientists have demonstrated that AR-12 can inhibit SARS-CoV-2 replication and are working to initiate clinical trials evaluating the antiviral drug.
Scientists have developed a new assay that uses nanoparticles to mimic how SARS-CoV-2 infects a cell, which could be used to screen for drugs that treat COVID-19.
Researchers have discovered how Tregs can reduce spinal cord injury caused by diseases like multiple sclerosis (MS).
A pocket in the SARS-CoV-2 Spike protein has been discovered by researchers, who say it could be a drug target for COVID-19.
Researchers report that removing the vSLFN gene from the ectromelia virus (ECTV) caused a potent immune response which protected animal models.
Scientists explore whether the anti-stress drug, 4-Phenylbutiric acid (4-PBA), could prevent cytokine storms causing respiratory failure in COVID-19 patients.
Having resolved the structure of psychedelic drugs bound to the 5-HT2A serotonin receptor researchers are now developing new therapeutic drugs.
